Price (delayed)
$0.235
Market cap
$28.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.42
Enterprise value
$10.76M
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium
There are no recent dividends present for BBI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.